HIGHLIGHTS  Application submitted for HREC approval to commence...

HIGHLIGHTS

 Application submitted for HREC approval to commence a Phase I clinical trial of EmtinB™

 The Phase I clinical trial will establish the safety profile, pharmacokinetics and pharmacodynamics of
EmtinB™ in up to 88 healthy adult volunteers

 The safety data from the clinical trial is also expected to support the progression of EmtinB™ into Phase
II clinical trials in patients for a range of neurodegenerative conditions in the future

 NeuroScientific recently achieved the historic milestones of HREC approval and first subject recruited
for its very first clinical trial for EmtinB™, an early-phase clinical trial in healthy volunteers
We have had no announcement to say that trials have begun,i believe their first recruit was the investor relations officer,we have had no further information on recruiting and the linear page has been changing its recruitment dates for months.